This week in dental tourism #11: what the Korean implant dominance actually means

The marketing materials of dental tourism clinics in Vietnam and Thailand reference implant brands in a specific way. The premium-tier clinics reference Straumann, Nobel Biocare, or Dentsply. The mid-tier clinics reference Korean brands, most commonly Osstem and MegaGen. The lower-tier clinics often list no brand at all, or list “Korean implants” as a category. What the marketing does not show is the market share distribution beneath the brand references, which is that Osstem and MegaGen, the established Korean mid-market systems, are the actual fixtures going into the majority of implant patients in the two highest-volume Asian dental tourism destinations, regardless of where the clinic is positioned in its own marketing.

This fact has two consequences that run in opposite directions, and holding both simultaneously is the column’s job this week. The first consequence is reassuring: the ten-year survival data on the established Korean systems is genuinely good, and the category dismissal of Korean implants as inferior is not supported by the evidence. The second consequence is alarming: the brand that dominates the legitimate mid-market is the brand most worth counterfeiting, and issue 6 of this column documented a manufacturer safety alert about counterfeit Osstem fixtures in the specific markets where Osstem dominates.

Both facts are true. A patient who hears only the first goes to Vietnam with false confidence that the brand name is sufficient assurance. A patient who hears only the second concludes that the Korean brands are dangerous when the genuine article is not. The column holds both.

What the survival data actually says

Published ten-year survival rates for dental implants need to be read carefully, because survival rates measure fixture retention, specifically whether the implant is still in place and in function at the stated interval, not absence of complications, not peri-implant health, not patient satisfaction [1] [2]. That methodological note is not a reason to dismiss the data; it is a reason to understand what the data measures.

For the established premium brands, Straumann and Nobel Biocare in particular, ten-year survival rates in the peer-reviewed literature cluster above 97% in well-selected patient populations, with the leading registry studies from Sweden and Switzerland reporting figures in the 97–99% range [1] [2]. These numbers are from long-running registries with rigorous follow-up and represent the best-evidenced baseline.

For the established Korean systems, Osstem and MegaGen specifically, the ten-year survival literature is smaller in absolute volume, partly because these brands achieved international penetration later, but the figures that exist are in the 93–97% range, depending on indication, bone quality, loading protocol, and study methodology [1] [2]. That is a genuine gap relative to the premium-brand upper end, but it is not a gap that, in isolation, justifies refusing the Korean mid-market tier for a patient who needs cost-effective treatment. A 95% ten-year survival rate is a defensible clinical outcome. It means that in a large majority of cases the fixture is still in function at a decade.

The honest clinical framing is this: the established Korean mid-market brands have a shorter published evidence history, a modestly lower survival rate in the literature as it currently exists, and a price point that is genuinely lower, which is why they dominate the dental tourism market. That is a reasonable trade-off for a patient who cannot afford the premium tier, provided the fixture is genuine and traceable and placed by a qualified clinician using appropriate technique. None of those provisos are automatic. All of them are assessable.

The category error in “European vs. Korean”

The binary that organises most patient-facing discussion of implant quality, European good, Korean lesser, is a category error that serves no one’s clinical interests. It conflates the manufacturer’s country of origin with fixture quality, when the actual determinants of outcome are the specific system’s published evidence, the provenance of the specific fixture, and the clinical skill of the operator who places it [1] [6].

A genuine, traceable Osstem fixture, placed in adequate bone by a qualified clinician using the manufacturer’s protocol, loaded within the evidence-supported timeline, is a defensible clinical choice. A counterfeit fixture wearing the Osstem brand name, placed by the same clinician, is a structural-risk problem, as issue 6 documents. The distinction between these two objects is not European versus Korean. It is genuine versus counterfeit. The European-Korean framing does not capture that distinction, because a counterfeit can wear either label.

This matters because the category error leads patients to the wrong question. “Did the clinic use a European implant?” is a question whose answer tells you the brand the clinic claims. It does not tell you whether the fixture is genuine, whether it is traceable to an authorised supply chain, or whether the brand name on the box corresponds to the material properties of the object inside the box. Issue 6 documented that counterfeit Osstem fixtures are packaged to look authentic [3] [4]. A patient asking “European or Korean?” would receive a passing answer from a clinic placing genuine Osstem and from a clinic placing a convincing counterfeit of Osstem. The question does not discriminate between them.

Why the dominant brand is the counterfeiting target

The counterfeit premium attaches to the high-volume mid-price product. This is the same economic logic this column applied in issue 6: a counterfeiter targets the fixture that is everywhere, because the unit economics of faking a widely distributed product are better than faking a niche one [3] [4]. Osstem is the volume leader in the Asian dental tourism mid-market. That market position is what makes it the economically rational target for a counterfeiting operation. MegaGen occupies a similar structural position in the tier below Osstem and faces a similar structural risk.

The clinics placing genuine Osstem under genuine supply-chain conditions are the majority. The clinics knowingly or unknowingly placing counterfeit fixtures under pressure from a compromised distributor are a minority whose size cannot be reliably estimated from outside the supply chain [3] [8]. The patient cannot distinguish the two by looking at the clinic’s marketing, because the clinic using genuine product and the clinic using counterfeit product are presenting the same brand name as the assurance. The brand name is precisely what the counterfeit copies [4]. This is the structural problem that the Osstem Hong Kong safety alert referenced in issue 6 makes concrete.

What a more precise patient conversation looks like

The conversation that would actually inform a patient making an implant decision is not “European or Korean?” It is a sequence of more specific questions.

Which system, specifically: not “Korean” but the fixture name, the reference number, and the manufacturer. “Osstem TS III SA, fixture reference TS4010” is a verifiable claim. “Korean implant” is not.

From what supply chain: not “we use Osstem” but “we purchase from [named authorised distributor], and we can show you our purchase documentation.” Osstem’s own guidance following the counterfeit alert specifies purchasing through authorised representatives [referenced in issue 6]. A clinic that has a named authorised-distributor relationship can answer this question. A clinic that cannot is a clinic where the supply-chain question has no documented answer.

What documentation travels home with the patient: the implant passport or patient card, carrying the system name, the fixture reference, the lot or serial identifier, and the placing clinician’s name, is the per-fixture record that establishes what was placed. A clinic that places genuine product has this as routine. A clinic that cannot produce it at discharge is a clinic where the provenance record ends at the operatory door.

These questions apply equally to European-branded and Korean-branded fixtures, because the issue is provenance and documentation, not country of origin. A genuine MegaGen with full documentation is clinically preferable to an unverified “European” fixture from an opaque supply chain. The patient who understands this has a better framework than the patient who is sorting by brand geography.

The peri-implantitis footnote

One clinical dimension the survival literature does not adequately capture is peri-implantitis, the inflammatory condition affecting peri-implant tissues that is the leading cause of late implant failure [7]. Peri-implantitis rates in the general implant population are high enough, some reviews report prevalence above 20% at ten years, that they represent a material clinical risk independent of fixture brand [7]. The risk is modifiable by surface preparation, placement technique, occlusal management, and patient hygiene compliance, none of which are captured in the brand-level survival data. A patient evaluating an implant proposal should understand that the survival curve, whether for an established Korean brand or a premium European one, does not tell them their personal peri-implantitis risk, which is partly fixture-dependent and substantially operator- and patient-dependent.

This column is not going to resolve the peri-implantitis literature in a weekly column item. The point is that the survival-rate comparison, 93–97% Korean vs. 97%+ European, is a legitimate data point and a limited one simultaneously. Fixture choice is one variable in a multi-variable outcome equation, and the variables the patient controls are not the fixture specification. They are the operator selection, the documentation chain, and the long-term maintenance commitment that follows the procedure regardless of where it was done.

The precise question, restated

The implant-brand conversation in dental tourism defaults to European versus Korean because it is the binary that the marketing supports and the patient can most easily ask. It is not the binary that matters. The question that matters is: is this specific fixture, from this specific supply chain, placed by this specific clinician, the genuine article it is represented to be? That question applies to every brand tier, and it is answered by documentation and supply-chain transparency, not by the manufacturer’s country of origin. The Korean mid-market, at its best, is clinically legitimate. At its worst, it is the most widely counterfeited fixture category in the highest-volume dental tourism markets in the world. Both of those facts are about the same brand tier, and they resolve to the same practical answer: the brand name is the beginning of the question, not the end of it.

Prior issues: issue 1 sets the framing. Issue 6 covers the Osstem counterfeit alert and supply-chain verification. Issue 8 covers the break-even arithmetic. Issue 9 covers the warranty paradox and BDA complication data. Issue 10 covers the Tbilisi anomaly and quality signalling in implant selection. For clinic-level fixture data: the Nhân Tâm Dental review, the Elite Dental review, and the Bangkok Hospital Dental Center review. For cost context: implant costs by country. For the peri-implantitis clinical picture: the peri-implantitis bone loss cascade treatment review.